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DepressionAbstract IPAH is a debilitating disease that is not curable and needs regular long term monitor-
ing, where the gold standard for diagnosing and monitoring patients, is right heart catheter.
Aim: Searching for the least invasive parameters possible to use as predictors of survival in
IPAH patients
Methodology: The study included 14 IPAH patients, for all PASP, SpO2, 6MWD, FC, PHQ9
depression score and targeted treatment pattern were assessed and the overall survival in 12, 24,
36, and 48 months in relation to the mentioned parameters was calculated.
Results: The overall survival was 64.29% in 12 months following diagnosis, 56.25% in
24 months, 46.88% in 36 months and 35.16% in 48 months. The overall survival was only statisti-
cally signiﬁcant in the groups of depression measured by PHQ-9. Most patients presented in func-
tional class II and III. Though SpO2, 6MWD and mono Versus combined therapy did not show
statistical signiﬁcance in the overall survival, yet there was obvious higher overall survival in
patients with SpO2P 90%, 6MWD> 300 m and in ﬁrst year of treatment with combined therapy.
Conclusion: The most signiﬁcant parameter affecting survival was depression score using PHQ-
9. It was also observed that the highest mortality was in the ﬁrst year of diagnosis although it was
not statistically signiﬁcant. Thus, a wider scale study is needed for the idiopathic pulmonary hyper-
tension patients to better assess their survival pattern.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Pulmonary arterial hypertension is a rare debilitating disease
characterized by progressive increase in pulmonary arterialpressure and pulmonary vascular resistance leading to right
ventricular failure and death [1]. The most commonly reported
symptoms on presentation in individuals with PAH are dysp-
nea and fatigue. These symptoms limit physical function,
and, by the time of diagnosis, most individuals have a marked
functional limitation [2]. The symptoms of dyspnea and fatigue
associated with PAH reﬂect both acute and chronic RVrculosis.
740 B.A. Naglaa et al.dysfunction, inﬂuence functional class and indirectly, predict
survival [3].
Although PAH cannot be cured, medical therapy often
allows the afﬂicted patient to live with the chronic illness, albeit
with varying degrees of impairment which is usually physical [4].
By time, patient reaches a stage of disability, including
physical and cognitive impairment as well as impaired quality
of life, which is related to several factors underlying their dis-
ease process [6]. This frequently accumulates a number of life
stressors that have been associated with development of
depression [5].
The level of symptoms on exertion is used by clinicians to
grade disease severity and prognosis in individuals with PAH
[3], aiming for practical management and predicting outcome
[7]. However many studies tackled this entity depending on
the patients’ hemodynamics based on performing right heart
catheterization [8–11], there were many patients who refused
performing invasive maneuvers [12].
Aim of work
Searching for the least invasive parameters possible that can be
used as predictors of survival in patients with idiopathic pul-
monary arterial hypertension.
Methodology
The studywas held in the Chest department, KasrAl-Aini hospi-
tal, Faculty ofMedicine, Cairo University, during the year 2011.
Fourteen patients diagnosed as Idiopathic pulmonary arte-
rial hypertension, were included in the study.
For all patients, certain parameters were used:
 PASP was used instead of m PAP as 6 patients out of
the 14 patients refused performing the right heart
catheter and pulmonary artery pressure was calculated
only by echocardiography.
 Functional classiﬁcation of pulmonary hypertension
modiﬁed after New York Heart Association functional
classiﬁcation according to WHO 1998 [13].
 6 minute walk distance was measured according to the
standards of the ATS guidelines [14] and was classiﬁed
into two groups either <300 m or P300 m.
 Oxygen saturation was measured by pulse oximetry at
time of presentation and was classiﬁed into two groups
<90% or P90%.
 Patient Health Questionnaire-9 (PHQ9) for assessment
of depression [15]. The results were sub classiﬁed into
none and mild versus moderate and moderately severe.
 Treatment pattern was followed whether being on
monotherapy or combined therapy.
 Calculating the survival time from time of diagnosis till
the ﬁrst of April 2015, in months or mentioning death
event.
 Descriptive data were tabulated. Mean, median, stan-
dard deviations, maximum and minimum were
calculated.
 Subcategories were presented in the form of absolute
numbers and percentage of the total study population.
 Survival analyses were statistically analyzed and
depicted as graphs.Results
Along 42 months, 75% survival in the group P300 m (no
median was reached) while 30% in group <300 m (median
survival 15.3 months) (no statistical signiﬁcance as p value
was 0.2383).
In the group with none/mild depression, survival was
62.5% (median survival 42.63 months).
And in the group with moderate/moderately severe depres-
sion survival was 16.67% (median survival 8.13 months).
(Statistically signiﬁcant with p value 0.048).
Along 4 years the group with SpO2 < 90 showed median
survival 15.31 with 16.67% survival while for SpO2P 90 the
median was not reached with 62.5% survival (No statistical
signiﬁcance).
Knowing that number of patients receiving monotherapy
were 10 (71.42%) in the form of sildenaﬁl, 4 patients received
combined therapy (28.58%) in the form of sildenaﬁl and
bosentan in 3 patients and sildenaﬁl and treprostinil in 1
patient.
The group of monotherapy showed median of
10.17 months with 40% survival along 4 years while the group
of combined therapy showed median of 32.53 months with
50% survival (No statistical signiﬁcance).
After 1 year 90% survival was found in combined therapy
and only 50% in the monotherapy group.
Discussion
The current study included 14 patients diagnosed as idiopathic
pulmonary arterial hypertension. The study population was
considered small which was attributed to the low incidence of
the disease all over the world, where the incidence rate was sta-
ted, approximately 2–6 cases/million populations/year in the
United States [16]. Recently the Registry to Evaluate Early
and Long-Term PAH Disease Management ‘‘REVEAL’’ reg-
istry stated an annual incidence of 1–2 cases per million people
in the US and Europe [17]. A prevalence of IPAH in France was
found to be about 6 cases/million populations [16]. The esti-
mated prevalence of PAH was found 15–50 cases/million [18],
where IPAH accounts for at least 40% of its cases [19].
Table 1 shows that the mean age was 29 ± 8.8 years, which
is consistent with the ﬁndings of Ni et al. (2009) who found the
mean age of the 108 IPAH patients was 32.5 ± 12.6 years [20].
Also Pugh & Hemnes (2010), stated mean age of
34.9 ± 36.3 months [21], and National Institutes of Health
(NIH) registry reported a mean ± SD age at diagnosis of
36 ± 15 years [22] while it was found in another age group
56 ± 16.4 years in other study [23]. Contemporary registry
data indicate that the average age of patients diagnosed with
PAH has increased, at least in the Western world [24].
Recent data from various PAH registries indicate that the
demographics of IPAH patients have changed. In the US
NIH registry in the 1980s PAH was typically diagnosed in
young adults [22] but more recent registry data depict a shift
toward diagnosing PAH in older patients [25–28].
There was evident female sex predilection as shown in
Table 2, where the female: male ratio was 6:1, (no: $= 12,
#= 2). It was found that, in the United States, the average
female-to-male ratio reported in clinical trials and registries
is close to 4:1 [17,21].
Table 1 Mean, median, SD, maximum and minimum of different variables in the study population.
N Mean Std. deviation Median Minimum Maximum
Age 14 29.00 8.814 30.00 16 46
6MWD 14 242.71 109.522 225.00 95 470
Duration of disease (years) 14 2.107 1.0034 2.000 .5 4.0
PHQ9 14 8.64 4.568 7.00 3 17
Overall survival (months) 14 25.1738 17.31831 23.8667 1.00 48.70
SpO2 14 88.93 7.457 92.50 73 96
PASP 14 75.6429 20.05227 70.0000 41.00 124.00
Duration of disease in years means duration of patients complain till the time of diagnosis.
Overall survival means the duration from the onset of diagnosis till the ﬁrst of April 2015.
Table 2 Number and percentage of different variable subcategories.
Sex 6MWD FC PHQ9 Outcome TTT SpO2
F M <300 P300 1 2 3 N-Mi M-MS Alive Dead mo co <90 P90
12 2 10 4 3 5 6 8 6 6 8 10 4 6 8
85.7 14.3 71.4 28.6 21.4 35.7 42.9 57.1 42.9 42.9 57.1 71.4 28.6 42.9 57.1
Outcome was assessed by the 1st of April 2015.
None – mild group in PHQ9 test: 3 patients with no depression.
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Figure 1 Line chart showing overall survival. Median: 32.53 SD:
18.36.
Least invasive parameters as predictors of survival in IPAH patients 741Although this female predilection remains unknown, some
hypotheses involve the role of sex hormones (estrogens), or an
X-linked locus in disease predisposition [29].
These patients had been complaining for a period of time of
mean 2.1 years before reaching a diagnosis (Table 1), which
was attributed to the insidious onset of the disease, nonspeciﬁc
complains of the disease and lack of awareness, both of the
patients and the physicians [30].
The overall survival as shown in Table 3 was 64.29% after
12 months, 56.25% after 24 months, 46.88% after 36 months
and 35.16% after 48 months. The ﬁrst year after diagnosis
had the highest percent of mortality [31]. This may be attribu-
ted to the difference in survival between incident cases and
prevalent ones. There was a rather increasing pattern of decli-
nation rate of annual survival over 12, 24, 36 months (8.04,
9.37, and 11.72) with a mean of decline at 9.71% of the study
population (Fig. 1).
If untreated, PAH is a fatal disease with a median survival
of 2.8 years in adults [32] while the data provided by the
‘‘REVEAL’’ demonstrate a 5-year survival of 68% in newly
or previously diagnosed PAH patients between 2006 and
2009 [33,34].
There were 3 patients (21.4%) who presented with func-
tional capacity (FC) class I, 5 (35.7%) with class II, and 6
(42.9%) with class III as shown in Table 2. Results show that,
the usual presentation of the disease occurs at FC class II and
III, which highlights the late presentation again [35].Table 3 Overall survival of the study population in different
periods.
After 12 months 64.29%
After 24 months 56.25%
After 36 months 46.88%
After 48 months 35.16%
Mean rate of annual decline = 9.71% of study population.Survival was recorded in the different subgroups as follows:
In Fig. 2, the group of 6MWD was divided into P300 m and
<300 m, because 300 m was considered as the point below
which the condition bears worse prognosis and prompt inten-
siﬁcation of treatment is required [36].
The end result survival in the subgroup <300 m was 30%
while those in group P300 m was 75% despite being insignif-
icant (p= 0.283), but it reﬂects limited exercise capacity in
subgroup <300 and detrimental effect on survival [36,37].
PHQ9 was conducted for all patients in the study at the
time of diagnosis with a mean score of 8.6 (Table 1) denoting
mild depression, highlighting the psychological burden on
these patients that adds to their physical limitation. [38].
Eight patients (57.1%) were included in the group of none to
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Figure 2 Line chart of each category overall survival regarding
6MWD.
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Figure 4 Line chart of each group overall survival regarding
oxygen saturation.
742 B.A. Naglaa et al.mild depression, (3 patients representing 21.4% with no
depression) and 6 patients (42.9%) had moderate to moder-
ately severe degree of depression, with no one having severe
depression (Table 2). The patients who had depression were
11 out of 14 (78.57%). A survey from Lowe et al. (2004), found
that at least one-third of pulmonary hypertension patients suf-
fer from a common and potentially treatable mental disorder,
with the major depressive disorders observed in 15.9% [39],
while another study estimated 26% of PAH patients had mod-
erate to severe symptoms of depression [40].
As for the survival rate (Fig. 3), there was a statistically sig-
niﬁcant difference between both groups (p= 0.048). In the
group with none/mild depression, survival was 62.5% (median
survival 42.63 months) and in the group with moderate/moder-
ately severe depression survival was 16.67% (median survival
8.13 months).
Patients with depression and/or chronic illness have an
increased risk of adverse outcomes [41]. Clinical depression is0 12 24 36 48
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Figure 3 Line chart of each subgroup overall survival regarding
PHQ-9.the strongest predictor for the development of medical disabil-
ity [42].
Being an important comorbidity in PAH, comprehensive
understanding of this disorder, became mandatory [43], to
improve patients’ and physician’s awareness, and encourage
reaching appropriate diagnosis and treatment of affected indi-
viduals [44].
In the current study, PASP mean was 75.6 ± 20 mmHg,
(Table1) and the mean SpO2 at time of diagnosis was 88%
(Table 1) (<90 was 42.9% (n= 6) while P90 was 57.1%
(n= 8)) as shown in Table 2. As shown in Fig. 4, the group
presenting with SpO2 < 90% showed 16.67% overall survival
in contrast to 62.5% in the group with SpO2P 90%. This was
thought to be due to a rather rapid deleterious effect of the dis-
ease that occurs within the early stages, leading to V/Q mis-
match, severe enough to cause hypoxia [45]. That is why the
patients usually present and being diagnosed in advanced func-
tional class [1]. If left untreated, PAH has a very poor progno-
sis [46].0 12 24 36 48
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Figure 5 Line chart of each group overall survival regarding
pattern of therapy (mono versus combined therapy).
Least invasive parameters as predictors of survival in IPAH patients 743Regarding the treatment pattern (Fig. 5), most patients
were receiving monotherapy (sildenaﬁl) (n= 10, %= 71.42)
and 4 patients received combined therapy (28.58%)
(Sildenaﬁl + bosentan or treprostinil). It was found that there
was no statistically signiﬁcant difference in survival.
However the pattern denotes better 1 year survival rate
among the group of combined therapy than those on
monotherapy.
Taichman et al. found that PAH patients were severely
impaired in both physical and mental dimensions of quality
of life [47]. Though studies showed a positive impact of tar-
geted therapy on >1 year survival [31], this was not the case
in the current study probably due to the small study group.
Conclusion
It was concluded from the current study that the most signiﬁ-
cant parameter affecting survival was depression score using
PHQ-9. It was also observed that the highest mortality was
in the ﬁrst year of diagnosis although it was not statistically
signiﬁcant. Most patients presented in functional classes 2
and 3 and patients presenting with SpO2P 90% had a better
survival though not statistically signiﬁcant. Thus, a wider scale
study is needed for the idiopathic pulmonary hypertension
patients to better assess their survival pattern.
Conﬂict of interest
We are searching for the possible least invasive parameters
that can be used as predictors of survival in patients with
idiopathic pulmonary arterial hypertension, in a trial to avoid
right sided cathetarization.AppendixName ____________ Date _______Over the last 2 weeks, how
often have you been
bothered by any of the
following problems?Not
at
allSeveral
daysMore
than half
the daysNearly
every
day1. Little interest or pleasure
in doing things0 1 2 32. Feeling down, depressed,
or hopeless0 1 2 33. Trouble falling or
staying asleep, or sleeping
too much0 1 2 34. Feeling tired or having
little energy0 1 2 35. Poor appetite or
overeating0 1 2 36. Feeling bad about
yourself––or that you are a
failure or have let yourself
or your family down0 1 2 37. Trouble concentrating
on things, such as reading
the newspaper or watching
television0 1 2 38. Moving or speaking so
slowly that other people
could have noticed? Or the
opposite––being so ﬁdgety
or restless that you have
been moving around a lot
more than usual0 1 2 39. Thoughts that you
would be better oﬀ dead or
of hurting yourself in some
way0 1 2 3Total: out of 27.
Depression Severity: 0–4 none, 5–9 mild, 10–14 moderate, 15–19
moderately severe, 20–27 severe. (10).References
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